Fisher & Paykel Healthcare (NZSE:FPH) COGS-to-Revenue : 0.39 (As of Sep. 2023)

View and export this data going back to 1979. Start your Free Trial

What is Fisher & Paykel Healthcare COGS-to-Revenue?

Fisher & Paykel Healthcare's Cost of Goods Sold for the six months ended in Sep. 2023 was NZ$318 Mil. Its Revenue for the six months ended in Sep. 2023 was NZ$816 Mil.

Fisher & Paykel Healthcare's COGS to Revenue for the six months ended in Sep. 2023 was 0.39.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Fisher & Paykel Healthcare's Gross Margin % for the six months ended in Sep. 2023 was 61.07%.

Fisher & Paykel Healthcare COGS-to-Revenue Historical Data

The historical data trend for Fisher & Paykel Healthcare's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fisher & Paykel Healthcare COGS-to-Revenue Chart

Fisher & Paykel Healthcare Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

COGS-to-Revenue

Get a 7-Day Free Trial

0.33

0.34

0.37

0.38

0.40

Fisher & Paykel Healthcare Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															0.38	0.39	0.40	0.41	0.39

Fisher & Paykel Healthcare COGS-to-Revenue Calculation

Fisher & Paykel Healthcare's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	642.7	/	1588.6
	=	0.40

Fisher & Paykel Healthcare's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	317.6	/	815.8
	=	0.39

Fisher & Paykel Healthcare (NZSE:FPH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Fisher & Paykel Healthcare's Gross Margin % for the six months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	317.6 / 815.8
	=	61.07 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Fisher & Paykel Healthcare COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fisher & Paykel Healthcare's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Fisher & Paykel Healthcare (NZSE:FPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fisher & Paykel Healthcare Corp Ltd (NZSE:FPH) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

FSPKF:USA FPLB:Germany FPH:Australia

Address

15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013

Website

https://www.fphcare.com

Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnoea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the U.S., 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.